Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jun 26, 2026

Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC

Jun 23, 2026

(R) Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital

Jun 11, 2026

Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC

Jun 10, 2026

Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study

Jun 5, 2026

(R) Cantargia publishes Information Document regarding Rights Issue of Shares

May 28, 2026

Cantargia AB to Host Webcast covering Rights Issue, Loan Agreement, and Strategic Priorities

May 28, 2026

(R) Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million

May 21, 2026

(R) Bulletin from the Annual General Meeting in Cantargia AB (publ)

May 19, 2026

(R) Cantargia publishes interim report for the first quarter of 2026

May 6, 2026

Invitation to the Presentation of Cantargia’s Interim Report for Q1 2026

Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye